-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245

Benzinga·08/24/2026 10:21:58
Listen to the news
HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $245.